Published in Biochim Biophys Acta on December 11, 2009
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proc Natl Acad Sci U S A (2010) 1.88
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia (2010) 1.81
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res (2011) 1.51
The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol (2010) 1.49
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics (2013) 1.47
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene (2011) 1.45
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol (2014) 1.32
mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle (2012) 1.25
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood (2011) 1.20
Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem (2012) 1.20
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol Neurodegener (2010) 1.18
mTor signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong? Physiology (Bethesda) (2011) 1.16
Altered metabolism and persistent starvation behaviors caused by reduced AMPK function in Drosophila. PLoS One (2010) 1.15
Regulation of mRNA translation by signaling pathways. Cold Spring Harb Perspect Biol (2012) 1.13
Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol (2012) 1.12
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J (2011) 1.11
Defining the role of TORC1/2 in multiple myeloma. Blood (2011) 1.10
The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) (2014) 1.10
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
AKT signaling pathway in the nucleus accumbens mediates excessive alcohol drinking behaviors. Biol Psychiatry (2011) 1.07
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget (2016) 1.02
Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet (2013) 1.02
Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program (2010) 1.01
ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change. J Exp Bot (2013) 0.97
Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer (2011) 0.97
PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med (2015) 0.96
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res (2014) 0.95
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One (2013) 0.94
mTOR Inhibition: From Aging to Autism and Beyond. Scientifica (Cairo) (2013) 0.94
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci (2015) 0.93
Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Respir Res (2014) 0.92
CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis (2014) 0.92
mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. J Neurochem (2014) 0.91
Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation. Mol Cell Biol (2013) 0.91
mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis (2015) 0.90
Activation of MAPK overrides the termination of myelin growth and replaces Nrg1/ErbB3 signals during Schwann cell development and myelination. Genes Dev (2014) 0.90
Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. Stem Cells Transl Med (2013) 0.90
Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. BMC Cancer (2013) 0.89
Expression profiling and functional analysis reveals that TOR is a key player in regulating photosynthesis and phytohormone signaling pathways in Arabidopsis. Front Plant Sci (2015) 0.89
mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res (2013) 0.88
Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1). J Biol Chem (2011) 0.88
Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci (2014) 0.88
MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma. Am J Pathol (2012) 0.87
Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Am J Cancer Res (2014) 0.87
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag (2013) 0.87
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol (2014) 0.86
Metabolic induction and early responses of mouse blastocyst developmental programming following maternal low protein diet affecting life-long health. PLoS One (2012) 0.85
Lysosomal accumulation of mTOR is enhanced by rapamycin. Histochem Cell Biol (2010) 0.85
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy. PLoS One (2014) 0.84
Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol (2015) 0.84
Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells. Cancer Gene Ther (2015) 0.83
Expression of a novel stress-inducible protein, sestrin 2, in rat glomerular parietal epithelial cells. Am J Physiol Renal Physiol (2014) 0.83
Pig immune response to general stimulus and to porcine reproductive and respiratory syndrome virus infection: a meta-analysis approach. BMC Genomics (2013) 0.83
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep (2015) 0.82
Luteinizing hormone/human chorionic gonadotropin-mediated activation of mTORC1 signaling is required for androgen synthesis by theca-interstitial cells. Mol Endocrinol (2012) 0.82
Rapamycin treatment improves neuron viability in an in vitro model of stroke. PLoS One (2013) 0.82
mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience (2015) 0.81
Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells. Biochem Biophys Res Commun (2011) 0.81
Lipidomic assessment of plasma and placenta of women with early-onset preeclampsia. PLoS One (2014) 0.81
Translational control of cyclins. Cell Div (2011) 0.81
mTOR pathway: A current, up-to-date mini-review (Review). Oncol Lett (2014) 0.81
Deficiency of a membrane skeletal protein, 4.1G, results in myelin abnormalities in the peripheral nervous system. Histochem Cell Biol (2017) 0.81
Functional regulation of PI3K-associated signaling in the accumbens by binge alcohol drinking in male but not female mice. Neuropharmacology (2016) 0.80
Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice. BMC Neurosci (2014) 0.80
Cytokines that promote nerve regeneration. Exp Neurol (2012) 0.80
Inhibition of mTOR Pathway by Rapamycin Reduces Brain Damage in Rats Subjected to Transient Forebrain Ischemia. Int J Biol Sci (2015) 0.80
The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers (Basel) (2010) 0.79
mTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Mol Cell Biol (2014) 0.79
BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget (2016) 0.78
RSK activation of translation factor eIF4B drives abnormal increases of laminin γ2 and MYC protein during neoplastic progression to squamous cell carcinoma. PLoS One (2013) 0.78
Ligands for FKBP12 increase Ca2+ influx and protein synthesis to improve skeletal muscle function. J Biol Chem (2014) 0.78
PF-4708671 activates AMPK independently of p70S6K1 inhibition. PLoS One (2014) 0.78
A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation. Methods Mol Biol (2012) 0.78
Essential role of D1R in the regulation of mTOR complex1 signaling induced by cocaine. Neuropharmacology (2015) 0.77
Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrology (Carlton) (2012) 0.77
Thyroid hormone-dependent development of early cortical networks: temporal specificity and the contribution of trkB and mTOR pathways. Front Cell Neurosci (2013) 0.77
Signalling mechanisms regulating phenotypic changes in breast cancer cells. Biosci Rep (2015) 0.77
The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer J (2012) 0.77
Role of mTOR, Bad, and Survivin in RasGAP Fragment N-Mediated Cell Protection. PLoS One (2013) 0.77
Coupling between Nutrient Availability and Thyroid Hormone Activation. J Biol Chem (2015) 0.76
Characterization of the altered gene expression profile in early porcine embryos generated from parthenogenesis and somatic cell chromatin transfer. PLoS One (2014) 0.76
Maternal nutrition modifies trophoblast giant cell phenotype and fetal growth in mice. Reproduction (2015) 0.76
Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice. PLoS One (2014) 0.76
Three distinct ribosome assemblies modulated by translation are the building blocks of polysomes. J Cell Biol (2015) 0.76
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer (2015) 0.76
A transplant patient with a swollen leg. Clin Kidney J (2012) 0.75
Amino Acid (Leucine) Chromatography: A Study of Branched-Chain Aminoaciduria in Type 2 Diabetes. Cureus (2017) 0.75
Unraveling the regulation of mTORC2 using logical modeling. Cell Commun Signal (2017) 0.75
Rational therapy from bench to bedside for a rare epilepsy. Epilepsy Curr (2014) 0.75
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget (2016) 0.75
The mTOR Complex Controls HIV Latency. Cell Host Microbe (2016) 0.75
mTOR kinase is needed for the development and stabilization of dendritic arbors in newly born olfactory bulb neurons. Dev Neurobiol (2016) 0.75
Bicaudal C mutation causes myc and TOR pathway up-regulation and polycystic kidney disease-like phenotypes in Drosophila. PLoS Genet (2017) 0.75
Inhibition of mTOR Kinase and Cancer Treatment. ACS Med Chem Lett (2013) 0.75
Metformin induces degradation of mTOR protein in breast cancer cells. Cancer Med (2016) 0.75
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06
Translational control in stress and apoptosis. Nat Rev Mol Cell Biol (2005) 8.91
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
Translational control of long-lasting synaptic plasticity and memory. Neuron (2009) 4.77
Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell (2009) 4.57
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science (2007) 4.33
A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A (2001) 4.16
Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol (2002) 4.11
Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell (2010) 4.01
Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes Dev (2005) 3.92
The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol (2003) 3.90
eIF4E--from translation to transformation. Oncogene (2004) 3.78
Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature (2010) 3.77
Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem (2005) 3.74
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell (2007) 3.46
The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol (2012) 3.42
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J (2004) 3.29
Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature (2012) 3.13
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell (2008) 3.10
Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol (2004) 3.00
14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature (2007) 2.98
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest (2007) 2.86
A new paradigm for translational control: inhibition via 5'-3' mRNA tethering by Bicoid and the eIF4E cognate 4EHP. Cell (2005) 2.80
Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol (2005) 2.80
Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature (2005) 2.67
miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol (2011) 2.61
Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation. Cell (2009) 2.60
Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol (2002) 2.53
A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay. J Cell Biol (2005) 2.51
A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap/Poly(A)-dependent translation. J Biol Chem (2002) 2.43
mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol (2011) 2.41
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol (2004) 2.38
eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nat Struct Mol Biol (2004) 2.38
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J Neurosci (2005) 2.33
Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A (2004) 2.32
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J (2007) 2.27
The dynamics of mammalian P body transport, assembly, and disassembly in vivo. Mol Biol Cell (2008) 2.25
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) (2008) 2.23
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One (2009) 2.20
Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell (2012) 2.19
The Akt of translational control. Oncogene (2005) 2.15
Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip Rev RNA (2010) 2.11
Reconstitution reveals the functional core of mammalian eIF3. EMBO J (2007) 2.06
Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J Neurosci (2006) 2.04
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest (2010) 2.04
Activation of GCN2 in UV-irradiated cells inhibits translation. Curr Biol (2002) 2.02
Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe (2011) 2.01
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci U S A (2005) 2.00
Two structurally atypical HEAT domains in the C-terminal portion of human eIF4G support binding to eIF4A and Mnk1. Structure (2006) 1.99
Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol (2005) 1.99
A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and functions in nonsense-mediated decay. Proc Natl Acad Sci U S A (2004) 1.97
A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity. Mol Cell Proteomics (2005) 1.95
Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol (2006) 1.93
Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol (2002) 1.92
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91
eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol (2006) 1.90
La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol Cell Biol (2004) 1.87
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
Starvation and oxidative stress resistance in Drosophila are mediated through the eIF4E-binding protein, d4E-BP. Genes Dev (2005) 1.84
Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J (2006) 1.79
S6K1 plays a critical role in early adipocyte differentiation. Dev Cell (2010) 1.74
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Signaling control of mRNA translation in cancer pathogenesis. Oncogene (2004) 1.71
Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA (2008) 1.69
Structural insights into the human GW182-PABC interaction in microRNA-mediated deadenylation. Nat Struct Mol Biol (2010) 1.66
Dendritic BC1 RNA: functional role in regulation of translation initiation. J Neurosci (2002) 1.64
Poly(A) binding protein (PABP) homeostasis is mediated by the stability of its inhibitor, Paip2. EMBO J (2006) 1.64
ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab (2008) 1.62
eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res (2012) 1.62
HuR protein attenuates miRNA-mediated repression by promoting miRISC dissociation from the target RNA. Nucleic Acids Res (2012) 1.58
Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem (2008) 1.57
Pervasive and cooperative deadenylation of 3'UTRs by embryonic microRNA families. Mol Cell (2010) 1.55
Paip1 interacts with poly(A) binding protein through two independent binding motifs. Mol Cell Biol (2002) 1.55
miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet (2010) 1.53
Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle (2007) 1.53
UNR, a new partner of poly(A)-binding protein, plays a key role in translationally coupled mRNA turnover mediated by the c-fos major coding-region determinant. Genes Dev (2004) 1.52
Structural basis of ligand recognition by PABC, a highly specific peptide-binding domain found in poly(A)-binding protein and a HECT ubiquitin ligase. EMBO J (2003) 1.52
Novel translational control in Arc-dependent long term potentiation consolidation in vivo. J Biol Chem (2009) 1.52